Zobrazeno 1 - 10
of 665
pro vyhledávání: '"Zoltán, Papp"'
Publikováno v:
ESC Heart Failure, Vol 11, Iss 3, Pp 1283-1289 (2024)
Abstract Heart failure is a devastating syndrome affecting an increasingly high number of patients worldwide. Its aetiology and pathogenesis are complex with the involvement of factors ranging from the genetic material through valvular dysfunctions t
Externí odkaz:
https://doaj.org/article/e0af5814423a4274a366a42adfd40ecb
Autor:
Zoltán Papp
Publikováno v:
Cardiologia Hungarica, Vol 54, Iss 3, Pp 174-176 (2024)
Az Európai Kardiológiai Társaság (ESC) minden évben megrendezi tavaszi csúcstalálkozóját, amely lehetőséget biztosít az ESC tagszervezeteinek, hogy kötetlen légkörben tekintsék át a szervezet céltevékenységeit. A 2024-es találkoz
Externí odkaz:
https://doaj.org/article/98e751dcee9146f9bdd92a266ea1a4a5
Autor:
Piero Pollesello, Zoltán Papp
Publikováno v:
European Science Editing, Vol 49, Iss , Pp 1-12 (2023)
The art of narrative and storytelling in scientific prose is now considered as an integral part of any well-rounded scientific communication process. Hence, when the AI-driven ChatGPT facility was made available online many scientists wanted to asses
Externí odkaz:
https://doaj.org/article/7b2c6bb94af447c6ae5daebb501d929b
Publikováno v:
ESC Heart Failure, Vol 10, Iss 4, Pp 2150-2158 (2023)
Abstract We witnessed major advances in the management of heart failure (HF) in 2022. Results of recent clinical and preclinical investigations aid preventive strategies, diagnostic efforts, and therapeutic interventions, and collectively, they hold
Externí odkaz:
https://doaj.org/article/d29f68b518b242418ed11fede811b8bd
Autor:
Arnold Péter Ráduly, Attila Tóth, Fruzsina Sárkány, Balázs Horváth, Norbert Szentandrássy, Péter P. Nánási, Zoltán Csanádi, István Édes, Zoltán Papp, Attila Borbély
Publikováno v:
ESC Heart Failure, Vol 10, Iss 2, Pp 1326-1335 (2023)
Abstract Aims Heart failure with reduced ejection fraction (HFrEF) is a disease with high mortality and morbidity. Recent positive inotropic drug developments focused on cardiac myofilaments, that is, direct activators of the myosin molecule and Ca2+
Externí odkaz:
https://doaj.org/article/884f94be9dcb4a8dbf784c50e3b45f24
Publikováno v:
ESC Heart Failure, Vol 10, Iss 4, Pp 2147-2149 (2023)
Externí odkaz:
https://doaj.org/article/46dec824d6334f618a421b999749a044
Autor:
Dorottya Kacsándi, Miklós Fagyas, Ágnes Horváth, Edit Végh, Anita Pusztai, Monika Czókolyová, Boglárka Soós, Attila Ádám Szabó, Attila Hamar, Zsófia Pethő, Nóra Bodnár, György Kerekes, Katalin Hodosi, Szilvia Szamosi, Gabriella Szűcs, Zoltán Papp, Zoltán Szekanecz
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
IntroductionThe Renin-Angiotensin-Aldosterone system (RAAS) has been implicated in the regulation of the cardiovascular system and linked to rheumatoid arthritis (RA). Little information has become available on the effects of Janus kinase (JAK) inhib
Externí odkaz:
https://doaj.org/article/f41fec7a849149948aedbbc135bef895
Autor:
Kitti Szőke, Beáta Bódi, Zoltán Hendrik, Attila Czompa, Alexandra Gyöngyösi, Donald David Haines, Zoltán Papp, Árpád Tósaki, István Lekli
Publikováno v:
Pharmacology Research & Perspectives, Vol 11, Iss 3, Pp n/a-n/a (2023)
Abstract Previous investigations have demonstrated that treatment of animals with rapamycin increases levels of autophagy, which is a process by which cells degrade intracellular detritus, thus suppressing the emergence of senescent cells, whose pro
Externí odkaz:
https://doaj.org/article/00e790af39c6412c9a663d092bf0f181
Autor:
Attila Nagy, Réka Májer, Judit Boczán, Sándor Sipka, Attila Szabó, Enikő Edit Enyedi, Ottó Tatai, Miklós Fagyas, Zoltán Papp, László Csiba, Attila Tóth
Publikováno v:
Biomedicines, Vol 11, Iss 12, p 3323 (2023)
Angiotensin–converting enzyme (ACE) inhibitors are the primarily chosen drugs to treat various cardiovascular diseases, such as hypertension. Although the most recent guidelines do not differentiate among the various ACE inhibitory drugs, there are
Externí odkaz:
https://doaj.org/article/48039e1fce5b4b209482220cad02c2d5
Autor:
Miklós Fagyas, Zsolt Fejes, Renáta Sütő, Zsuzsanna Nagy, Borbála Székely, Marianna Pócsi, Gergely Ivády, Edina Bíró, Gabriella Bekő, Attila Nagy, György Kerekes, Zoltán Szentkereszty, Zoltán Papp, Attila Tóth, János Kappelmayer, Béla Nagy, Jr.
Publikováno v:
International Journal of Infectious Diseases, Vol 115, Iss , Pp 8-16 (2022)
Objectives: Angiotensin-converting enzyme 2 (ACE2) represents the primary receptor for SARS-CoV-2 to enter endothelial cells. Here we investigated circulating ACE2 activity to predict the severity and mortality of COVID-19. Methods: Serum ACE2 activi
Externí odkaz:
https://doaj.org/article/e66c5aaf070048b0bb2bb110f12d9088